# A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

Submission date	Recruitment status	Prospectively registered
19/08/2002	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
19/08/2002	Completed	Results
Last Edited	Condition category	Individual participant data
11/01/2019	Cancer	Record updated in last year

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

### Contact name

Dr - -

### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

LK/FIL

# Study information

### Scientific Title

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

# **Study objectives**

Not provided at time of registration

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Not provided at time of registration

# Study design

Randomised controlled trial

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Not specified

# Study type(s)

**Not Specified** 

# Participant information sheet

# Health condition(s) or problem(s) studied

Leukaemia (acute), Leukaemia (chronic)

### **Interventions**

- 1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products
- 2. Arm B: Patients receive Pall filtered blood or platelet donations

# Intervention Type

Drug

# **Phase**

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Leukocyte-Depleted Red Cell and Platelet Donations

# Primary outcome measure

Not provided at time of registration

# Secondary outcome measures

Not provided at time of registration

# Overall study start date

01/01/1990

# Completion date

01/04/1992

# Eligibility

# Key inclusion criteria

- 1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma
- 2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible
- 3. Any age
- 4. Fit to undergo the treatments as defined in protocol

# Participant type(s)

**Patient** 

# Age group

**Not Specified** 

### Sex

**Not Specified** 

# Target number of participants

Not provided at time of registration

# Key exclusion criteria

Not provided at time of registration

### Date of first enrolment

01/01/1990

## Date of final enrolment

01/04/1992

# Locations

### Countries of recruitment

England

**United Kingdom** 

# **UKCCCR Register Co-ordinator**

London United Kingdom NW1 2DA

# Sponsor information

# Organisation

Pall Biomedical Ltd (UK)

# Sponsor details

Europa House Havant Street Portsmouth United Kingdom PO1 3PD

# Sponsor type

Industry

### Website

http://www.pall.com/

### **ROR**

https://ror.org/04hw9y579

# Funder(s)

# Funder type

Industry

# **Funder Name**

Pall Biomedical Ltd (UK)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration